Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

168.67B

Market cap168.67B

Price-Earnings ratio

21.05

Price-Earnings ratio21.05

Dividend yield

2.32%

Dividend yield2.32%

Average volume

8.00M

Average volume8.00M

High today

$136.30

High today$136.30

Low today

$131.00

Low today$131.00

Open price

$131.28

Open price$131.28

Volume

13.18M

Volume13.18M

52 Week high

$136.30

52 Week high$136.30

52 Week low

$92.26

52 Week low$92.26

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $135.93, giving the company a market capitalization of 168.67B. It carries a P/E multiple of 21.05 and pays a dividend yield of 2.3%.

On 2026-01-25, Gilead Sciences(GILD) stock moved within a range of $131.00 to $136.30. With shares now at $135.93, the stock is trading +3.8% above its intraday low and -0.3% below the session's peak.

Trading activity shows a volume of 13.18M, compared to an average daily volume of 8M.

The stock's 52-week range extends from a low of $92.26 to a high of $136.30.

GILD News

Simply Wall St 2d

How Investors May Respond To Gilead Sciences Trodelvy Keytruda Breast Cancer Data In NEJM

Gilead Sciences announced that The New England Journal of Medicine has published full Phase 3 ASCENT-04/KEYNOTE-D19 results, showing Trodelvy plus Keytruda impr...

Simply Wall St 4d

Gilead Sciences Valuation Check After Trodelvy Keytruda Phase 3 Success And Regulatory Progress

Gilead Sciences (GILD) is back in focus after detailed Phase 3 ASCENT-04/KEYNOTE-D19 results in The New England Journal of Medicine showed that Trodelvy plus Ke...

TipRanks 4d

Gilead announces NEJM Phase 3 study data for Trodelvy+Keytruda

The company states: “Gilead (GILD) Sciences announced The New England Journal of Medicine published the full results from the positive Phase 3 ASCENT-04/KEYNOTE...

Analyst ratings

76%

of 29 ratings

Buy

75.9%

Hold

24.1%

Sell

More GILD News

Simply Wall St 5d

Gilead’s Yeztugo Approval Highlights HIV Growth And Acquisition-Fueled Upside

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Yeztugo, a twice-yearly injectable for HIV prevention. The company has started the commercial rollout...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.